Boston Scientific Corp
BSX
View Detailed Chart
99.870USD
-2.840-2.77%
Close 09/15, 16:00（ET）Quotes delayed by 15 min
147.84BMarket Cap
59.02P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-2.77%
5 Days
-7.65%
1 Month
-3.20%
6 Months
+2.79%
Year to Date
+11.81%
1 Year
+19.88%
View Detailed Chart
TradingKey Stock Score
Currency: USD Updated：2025-09-12Key Insights
The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
36
analysts
Buy
Current Rating
123.771
Target Price
+20.50%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. Its MedSurg segment includes Endoscopy, Urology and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a broad range of gastrointestinal (GI) and pulmonary conditions with less invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. Its Interventional Cardiology Therapies business develops and manufactures technologies for diagnosing and treating coronary artery disease and aortic valve conditions. It also owns the transcarotid artery revascularization (TCAR) platform.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 32.05% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 188.63.
Undervalued
The company’s latest PE is 60.53, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 1.39B shares, increasing 0.01% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 136.47M shares of this stock.
Financial Indicators
EPS
No Data
Total revenue
No Data
Company
Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. Its MedSurg segment includes Endoscopy, Urology and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a broad range of gastrointestinal (GI) and pulmonary conditions with less invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. Its Interventional Cardiology Therapies business develops and manufactures technologies for diagnosing and treating coronary artery disease and aortic valve conditions. It also owns the transcarotid artery revascularization (TCAR) platform.
Ticker SymbolBSX
CompanyBoston Scientific Corp
CEOMr. Michael F. (Mike) Mahoney
Websitehttps://www.bostonscientific.com/en-US/Home.html
Related Instruments
-1.04%
-3.49%
-0.79%
-0.06%
-1.96%
+0.39%
+1.94%
+1.73%
-0.11%
+1.24%
+6.10%
-1.01%
+1.36%
-2.04%
+3.75%
-0.24%
-1.13%
+0.09%
+1.23%
+1.35%
